SEC Form 4 · accession 0001209191-18-035882
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Margaret G McGlynn
Director
Period of report
Jun 1, 2018
Accepted (ET)
Jun 5, 2018 · 5:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 1, 2018 | A | 1,801 | $0.00 | A | 8,113 | D | |
| Common StockF2 | Jun 1, 2018 | D | 2,188 | — | D | 5,925 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $152.74 | Jun 1, 2018 | A | 3,229 | A | — | May 31, 2028 | Common Stock | 3,229 | 3,229 | D |
| Deferred Stock UnitsF2,F4 | — | Jun 1, 2018 | A | 2,188 | A | — | — | Common Stock | 2,188 | 2,188 | D |
Explanation of responses
- F1Restricted stock unit that vests, subject to certain limited exceptions, on the first anniversary of the grant date.
- F2Upon the vesting of restricted stock units granted to Ms. McGlynn on June 1, 2017, Ms. McGlynn deferred the receipt of 2,188 shares of common stock and received instead 2,188 deferred stock units pursuant to the Company's deferred compensation plan. As a result, Ms. McGlynn is reporting the disposition of 2,188 shares of common stock in exchange for an equal number of deferred stock units.
- F3Fully vested.
- F4Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McGlynn's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McGlynn's disability or death.